Standalone Financial Results (₹ lakhs)

Income Statement

  • Revenue from operations: ₹21.15 (newly commenced during the quarter)
  • Other income: ₹43.00 (compared to ₹22.92 in Q1 FY26 and ₹37.41 in Q4 FY26)
  • Total income: ₹64.15 (compared to ₹22.92 in Q1 FY26 and ₹37.41 in Q4 FY26)

Expenses

  • Purchases of stock-in-trade: ₹24.39
  • Changes in inventories: (₹3.65) credit
  • Employee benefit expenses: ₹11.19 (compared to ₹4.30 in Q1 FY26)
  • Finance cost: ₹0.12
  • Depreciation and amortization: ₹1.44 (compared to ₹1.68 in Q1 FY26)
  • Other expenses: ₹8.49 (compared to ₹7.09 in Q1 FY26)
  • Total expenses: ₹41.98

Profitability

  • Profit before tax: ₹22.17 (compared to ₹9.75 in Q1 FY26 and ₹14.55 in Q4 FY26)
  • Tax expense: ₹0.70 (Current tax: ₹0.76, Deferred tax: (₹0.06) credit)
  • Net profit for period: ₹21.47 (compared to ₹9.84 in Q1 FY26 and ₹9.49 in Q4 FY26)
  • Total comprehensive income: ₹21.47

Capital Structure and Metrics

  • Paid-up equity share capital: ₹559.12 lakh (face value ₹10 each)
  • Reserves (as of March 31, 2026): ₹1,568.23 lakh
  • Basic EPS: ₹0.38 (not annualized)
  • Diluted EPS: ₹0.38 (not annualized)

Consolidated Financial Results

Entity Composition

The consolidated results include:

  • Parent: Relic Technologies Limited
  • Subsidiaries: Relic Pharma Limited and Truhealthy Wellness Private Limited

Subsidiary Performance (Quarter ended June 30, 2026)

  • Total revenues: ₹14.34 lakh
  • Total net loss after tax: ₹(124.22) lakh
  • Total comprehensive income: ₹(122.75) lakh

Notes to Financial Results

1. Financial results prepared in accordance with Ind AS 34 (Interim Financial Reporting) and SEBI Listing Regulations.

2. The company commenced revenue from operations during the quarter through trading activities in pharmaceuticals, nutraceuticals, wellness products, healthcare products, chemicals and allied products.

3. The company is engaged in a single business segment.

4. Figures for quarter ended March 31, 2026 are balancing figures between audited annual figures and previously published unaudited nine-month figures.

5. Previous periods' figures have been regrouped and reclassified where necessary.

Auditor Review

D. Kothary & Co., Chartered Accountants, conducted limited review of both standalone and consolidated financial results and issued an unmodified conclusion stating nothing came to their attention suggesting material misstatement. The review was conducted in accordance with SRE 2410.